A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
ATTR cardiac amyloidosis
Amyloid
Japanese Circulation Society
Japanese Ministry of Health, Labour and Welfare (JMHLW)
Tafamidis
Journal
Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683
Informations de publication
Date de publication:
25 12 2019
25 12 2019
Historique:
pubmed:
19
11
2019
medline:
18
9
2020
entrez:
19
11
2019
Statut:
ppublish
Résumé
Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel
Identifiants
pubmed: 31735731
doi: 10.1253/circj.CJ-19-0811
doi:
Substances chimiques
Benzoxazoles
0
tafamidis
8FG9H9D31J
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-17Commentaires et corrections
Type : CommentIn
Type : CommentIn